AstraZeneca announced changes in its top management team in an official statement released today.The crucial post of president of research and development, currently held by the departing Martin Mackay, is to be eliminated and replaced by three individuals responsible for different pharmaceutical segments.

In addition, the company's top sales executive, Executive Vice President of Global Commercial Tony Zook, is to leave the company. His position will also be eliminated and carried out by three managers, each responsible for a different commercial region -- North America, Europe, and international.

The shakeup comes several months after the appointment of current CEO Pascal Soriot, who took his position last summer following the sudden retirement of his predecessor, David Brennan.

The article AstraZeneca Reshuffles Management Team originally appeared on

Eric Volkman and The Motley Fool have no position in AstraZeneca. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Increase your money and finance knowledge from home

Investor’s Toolbox

Improve your investing savvy with the right financial toolset.

View Course »

Investing in Startups

The lucrative and risky world of startups.

View Course »

Add a Comment

*0 / 3000 Character Maximum